ABOUT ISLET SCIENCES

Islet Sciences, Inc. is developing new medicines and technologies for the treatment of metabolic diseases.

The Company’s current pipeline includes first in class immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflammation, a cell therapy based artificial pancreas for the treatment of type 1 diabetes, and a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the early detection of the onset of type 1 diabetes or insulin dependent type 2 diabetes.

Islet Sciences’ mission is to improve patient outcomes by transforming great science into actionable solutions for the treatment of metabolic disease.

DAVID WILDER
COO & CFO

GENE MANNHEIMER
DIRECTOR

GARY KEELING
DIRECTOR

JOHN STEEL
DIRECTOR

THOMAS J. KINDT, PH.D.
SCIENTIFIC ADVISORY BOARD

KEVIN HEROLD, M.D.
SCIENTIFIC ADVISORY BOARD

MENG TAN, M.D.
SCIENTIFIC ADVISORY BOARD

ALAN CHERRINGTON, PH.D.
SCIENTIFIC ADVISORY BOARD

CHRISTIAN MENDE, M.D.
SCIENTIFIC ADVISORY BOARD

ZAN FLEMING, M.D.
SCIENTIFIC ADVISORY BOARD

Type 2 Diabetes

Type 2 diabetes is a progressive metabolic disorder characterized by insulin insensitivity, relative insulin deficiency, consequent hyperglycemia and increased incidence of cardiovascular complications. T2DM, sometimes referred to as adult-onset diabetes, accounts for ~90% of all diagnosed cases of diabetes and is a lifelong disease for which there is no known cure. Patients are typically treated using a combination of prescribed exercise, dietary modification and drug therapies.

It is estimated that patients with diabetes have medical expenditures that are over 2 times higher than those without diabetes. Total healthcare related costs for the treatment of diabetes are estimated at ~$175 billion with $116 billion attributable to direct medical costs and $58 billion from indirect costs such as disability payments, lost productivity, and premature death. Currently available diabetes treatments have many drawbacks, including tolerability issues, weight gain, and loss of efficacy over time (diabetes therapies are typically taken in combination to help prolong their effectiveness). There remains a vast unmet need for new oral, insulin independent treatments for patients with T2DM.

Type 1 Diabetes

Type 1diabetes is an autoimmune disorder where the immune system attacks and destroys insulin-producing islet cells of the pancreas. These cells are created shortly after birth and cannot repair themselves if damaged.

5-10% of all diabetes cases are insulin-dependent and approximately one in every 400-500 children and adolescents is diagnosed with the disease.

Current treatments for Insulin Dependent Diabetes are palliative and require constant glucose monitoring and repeated daily insulin injections. In contrast, the transplantation of glucose-producing pancreatic islet cells could allow patients to become independent of injected insulin and eliminate the need for constant monitoring of their blood glucose levels.

Yale scientists, under the direction of Professor Kevan Herold, have identified a biomarker for ongoing cell death, and developed a non-invasive diagnostic test that can detect cell loss in vivo earlier than current functional tests.

Islet Science seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Islet Sciences is traded on the OTC under the ticker symbol ISLT.

VIEW DETAILED INVESTOR INFORMATION >>